NasdaqGS - Nasdaq Real Time Price USD
Metagenomi, Inc. (MGX)
1.6100
+0.1200
+(8.05%)
At close: May 2 at 4:00:01 PM EDT
1.6200
+0.01
+(0.62%)
After hours: May 2 at 6:56:13 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 4 |
| Avg. Estimate | -0.51 | -0.56 | -2.33 | -2.23 |
| Low Estimate | -0.52 | -0.57 | -2.43 | -3.34 |
| High Estimate | -0.5 | -0.56 | -2.28 | -0.54 |
| Year Ago EPS | -2.08 | -0.29 | -2.36 | -2.33 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 6 |
| Avg. Estimate | 7.96M | 8.52M | 31.91M | 34.13M |
| Low Estimate | 2.5M | 2.5M | 10M | 10M |
| High Estimate | 10M | 12.1M | 46.6M | 68M |
| Year Ago Sales | 11.16M | 20.01M | 52.3M | 31.91M |
| Sales Growth (year/est) | -28.67% | -57.42% | -38.98% | 6.95% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.68 | -0.81 | -0.74 | -0.78 |
| EPS Actual | -2.08 | -0.29 | -0.51 | -0.63 |
| Difference | -1.4 | 0.52 | 0.23 | 0.15 |
| Surprise % | -207.97% | 64.34% | 31.31% | 18.97% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.51 | -0.56 | -2.33 | -2.23 |
| 7 Days Ago | -0.69 | -0.75 | -2.37 | -2.31 |
| 30 Days Ago | -0.69 | -0.75 | -2.36 | -2.24 |
| 60 Days Ago | -0.69 | -0.75 | -2.88 | -2.06 |
| 90 Days Ago | -0.69 | -0.75 | -2.88 | -2.06 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | 2 | 2 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MGX | 75.47% | -94.83% | 1.27% | 4.29% |
| S&P 500 | 12.40% | 3.81% | 8.28% | 13.79% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/3/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/18/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 12/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/21/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/15/2024 |
Related Tickers
PRME Prime Medicine, Inc.
1.6800
-3.45%
KYTX Kyverna Therapeutics, Inc.
2.2800
+2.70%
GPCR Structure Therapeutics Inc.
27.09
-0.88%
ACRV Acrivon Therapeutics, Inc.
1.4100
+6.02%
BOLD Boundless Bio, Inc.
1.6050
-0.31%
BPMC Blueprint Medicines Corporation
104.64
+5.43%
FATE Fate Therapeutics, Inc.
1.3100
+5.65%
LXEO Lexeo Therapeutics, Inc.
4.6400
-1.49%
KYMR Kymera Therapeutics, Inc.
35.28
+2.11%
FDMT 4D Molecular Therapeutics, Inc.
3.7600
+9.30%